(A) DIO Klbfl/fl and KlbAdipoq littermates were treated with FGF21 or vehicle during a hyperinsulinemic-euglycemic clamp and glucose infusion rate, endogenous glucose production and whole-body glucose uptake during the clamp and basal endogenous glucose production measured. n = 5–6/group.
(B) DIO Klbfl/fl and KlbAdipoq littermates were treated with FGF19 or vehicle during a hyperinsulinemic-euglycemic clamp and glucose infusion rate, endogenous glucose production and whole-body glucose uptake during the clamp and basal endogenous glucose production measured. n = 6–8/group.
Data are shown as the mean ± SEM. *p < 0.05, **p < 0.01 compared to control. Significant interactions between genotype (Klbfl/fl vs. KlbAdipoq) and treatment (Vehicle vs. FGF21) were detected for glucose infusion rate (p=0.03) and endogenous glucose production (p=0.02).
See also Table S1.